Oh Byeong Seob, Choi Won Jung, Kim Ji-Sun, Ryu Seoung Woo, Yu Seung Yeob, Lee Jung-Sook, Park Seung-Hwan, Kang Se Won, Lee Jiyoung, Jung Won Yong, Kim Young-Min, Jeong Jae-Ho, Lee Ju Huck
Korean Collection for Type Cultures, Biological Resource Center, Korea Research Institute of Bioscience and Biotechnology, Jeongeup, South Korea.
Korean Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, South Korea.
Front Microbiol. 2021 Nov 11;12:736343. doi: 10.3389/fmicb.2021.736343. eCollection 2021.
The gut microbiota (GM) has been shown to be closely associated with the development of colorectal cancer (CRC). However, the involvement of GM is CRC has mainly been demonstrated by metagenomic profiling studies showing the compositional difference between the GM of healthy individuals and that of CRC patients and not by directly studying isolated gut microbes. Thus, to discover novel gut microbes involved in CRC, we isolated the GM from the feces of healthy individuals and evaluated its anti-CRC activity and . After GM isolation, cell-free supernatants (CFSs) were prepared from the isolated gut microorganisms to efficiently screen a large amount of the GM for anti-proliferative ability . Our results showed that the CFSs of 21 GM isolates had anti-proliferative activity against human colon cancer HCT 116 cells. Of these 21 GM isolates, GM07 was chosen for additional study because it had the highest anti-cancer activity against mouse colon cancer CT 26 cells and was further evaluated in a CT 26 allograft mouse model . GM07 was identified as through phylogenetic analysis based on 16S rRNA gene sequencing. Further investigation determined that the CFS of (OsCFS) induced anti-proliferative activity apoptosis, but not cell cycle arrest. Moreover, GC/MS analysis suggested that the putative active molecule in OsCFS is malic acid. Finally, in the CRC mouse model, peri-tumoral injection of OsCFS significantly decreased CRC formation, compared to the control group. Altogether, these findings will provide valuable information for the discovery of potential probiotic candidates that inhibit CRC.
肠道微生物群(GM)已被证明与结直肠癌(CRC)的发生密切相关。然而,GM在CRC中的作用主要是通过宏基因组分析研究来证明的,这些研究显示了健康个体和CRC患者的GM之间的组成差异,而不是通过直接研究分离出的肠道微生物。因此,为了发现参与CRC的新型肠道微生物,我们从健康个体的粪便中分离出GM,并评估其抗CRC活性。GM分离后,从分离出的肠道微生物中制备无细胞上清液(CFSs),以有效地筛选大量GM的抗增殖能力。我们的结果表明,21种GM分离株的CFSs对人结肠癌HCT 116细胞具有抗增殖活性。在这21种GM分离株中,GM07因其对小鼠结肠癌CT 26细胞具有最高的抗癌活性而被选作进一步研究,并在CT 26同种异体移植小鼠模型中进行了进一步评估。通过基于16S rRNA基因测序的系统发育分析,GM07被鉴定为 。进一步的研究确定, (OsCFS)的CFS诱导抗增殖活性 凋亡,但不诱导细胞周期停滞。此外,GC/MS分析表明,OsCFS中假定的活性分子是苹果酸。最后,在CRC小鼠模型中,与对照组相比,瘤周注射OsCFS显著减少了CRC的形成。总之,这些发现将为发现抑制CRC的潜在益生菌候选物提供有价值的信息。